期刊文献+

HPLC法测定人血清中利奈唑胺浓度及其临床应用 被引量:22

HPLC determination and clinical application of linezolid concentration in human serum
原文传递
导出
摘要 目的:建立高效液相色谱法快速测定人血清中利奈唑胺浓度,并用于危重患者治疗药物监测。方法:色谱柱:Hypersil ODS柱;流动相:乙腈-水(23:77),调整pH至5.0;流速:1.0mL.min-1;紫外检测波长为254nm。应用已建立的方法对9例危重患者进行利奈唑胺治疗药物监测,并合理制定个体化给药方案。结果:利奈唑胺在0.31~20.00mg.L-1浓度范围内线性关系良好(r=0.9996),最低定量限为0.31mg.L-1,绝对回收率为47.2%,相对回收率为102.1%,日内、日间精密度的RSD分别<4%和<3.5%。另外,所监测9例危重患者中,有4例患者出现利奈唑胺谷浓度小于最低抑菌浓度的情况。结论:HPLC法简单、快速、准确、灵敏、重现性好,可用于临床利奈唑胺的浓度监测。 Objective:To establish a method of determining serum linezolid in human by HPLC,and use the method for therapeutic drug monitoring in critically ill patients.Methods:Separation was carried out on a Hypersil ODS column,the mobile phase consisted of acetonitrile-water (23∶77),adjust the pH to 5.0 at the flow rate of 1.0 mL/min-1.UV detection wavelength was 254 nm.The method has been used for nine critically ill patients for therapeutic drug monitoring,and individual dosage regimen of linezolid.Results:A good linearity was demonstrated between 0.31-20.00 mg/L-1 (r=0.9996),the lowest limit of quantification of 0.31 mg/L-1.The absolute recovery was 47.2%,and the relative recovery was 102.1%.The intra-day and inter-day deviation was showed by RSD〈4%,〈3.5%,respectively.In addition,the monitoring of nine critically ill patients,there are four patients with linezolid trough concentrations less than the minimum inhibitory concentrations.Conclusion:The method is simple,rapid,accurate,sensitive,reproducible,and validated for determination of serum linezolid in clinical practice.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第2期199-203,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 利奈唑胺 高效液相色谱法 血药浓度 治疗药物监测 linezolid HPLC blood drug concentration therapeutic drug monitoring
  • 相关文献

参考文献27

  • 1Abena PA, Mathieux VG, Scheiff JM, et al. Linezolid and reversible myelosuppression. J Am Med Assoc ,2001,286 : 1973.
  • 2Santos RP, Prestidge CB, Brown ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pul- mortology,2009,44(2) : 148.
  • 3Lovering AM, Le FR, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother,2009,63 ( 3 ) :553.
  • 4Brier ME, Stalker D J, Aronoff GR, et al. Pharmaeokineties of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother, 2003,47 (9) :2775.
  • 5Tsuji Y, Hiraki Y, Mizoguchi A ,et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother, 2008,14 ( 2 ) : 156.
  • 6Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of staphylococcus aureus. Lancet ,2001,358:207.
  • 7Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin -resistant Staphylococcus aureus:treatment failure with linezolid. Clin Infect Dis ,2002,35:1018.
  • 8Gonzales RD, Schreckenberger PC, Graham MB,et al. Infections due to vancomycin - resistant enterococcus faecium resistant to linezolid. Lancet ,2001,357 : 1179.
  • 9Attassi K, Hershberger E, Alam R,et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis ,2002,34:695.
  • 10MacGowan AP. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother, 2001,48 ( Suppl SI ) : 17.

同被引文献144

引证文献22

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部